What are the cardiovascular and renal outcomes associated with telmisartan, ramipril, or both in people at high renal risk?
The cardiovascular and renal outcomes associated with telmisartan, ramipril, or both in people at high renal risk were studied in the ONTARGET and TRANSCEND studies. Results from these studies showed that telmisartan plus ramipril was more effective than either drug alone in reducing the risk of cardiovascular events, stroke, and death. It was also associated with a reduction in renal events, though this was not statistically significant. Additionally, telmisartan alone had a greater effect on systolic blood pressure compared to ramipril alone. Overall, telmisartan plus ramipril was found to have the most benefit for people at high renal risk. (Source: Circulation. 2011;123:1098 1107.)